Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 886

Sort by

Sort Order Select

Journal Articles

Live or die: PD-L1 delays neutrophil apoptosis

Jamel El-Benna, Pham My-Chan Dang

Blood (2021) 138 (9): 744–746.

https://doi.org/10.1182/blood.2021012186

Published: 2021

Journal Articles

Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress

Lei Zhang, PhD, Huacheng Luo, PhD, Jing Li, Hong-Min Ni, Mark Sellin, Feng Zhang, Jun Zhang, Peter Breslin, PhD, Wei Wei, William Small, Jr., Wen-Xin Ding, Suming Huang, PhD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 3714.

https://doi.org/10.1182/blood-2019-131332

Published: 2019

Journal Articles

Expression of Human SBDS R126T in S bds Null Background Shows Eif6 Dysregulation: An Adult Zebrafish Model for Shwachman-Diamond Syndrome

Usua Oyarbide Cuervas-Mons, PhD MSc, BSc, Matthew Snyderman, MSc, Jacek Topczewski, PhD, Seth J. Corey, MD

Blood (2019) 134 (Supplement_1): 3737.

https://doi.org/10.1182/blood-2019-129014

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Sirpαfc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

Oleksandr Galkin, PhD, Jessica McLeod, BSc, James A Kennedy, MD PhD, Liqing Jin, MD, Nathan Mbong, Mark Wong, PhD, Bob Uger, PhD, Mark D. Minden, MD PhD, Jayne S Danska, PhD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 3906.

https://doi.org/10.1182/blood-2019-131018

Published: 2019

Journal Articles

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Valentina Gaidano, MD, Paola Circosta, PhD, Alessandro Cignetti, MD PhD, Mohammad Houshmand, Nicoletta Vitale, PhD, Stefano Sainas, PhD, Agnese Pippione, PhD, Manuela Marraudino, PhD, Brigitta Bonaldo, MD, Marta Giorgis, PhD, Donatella Boschi, PhD, Marco Lucio Lolli, PhD, Giuseppe Saglio, MD

Blood (2019) 134 (Supplement_1): 3942.

https://doi.org/10.1182/blood-2019-128085

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

N. Nora Bennani, MD, Grzegorz Nowakowski, MD, Lisa M. Rimsza, MD, Alex A Adjei, MD PhD, Laurence Doyle, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4090.

https://doi.org/10.1182/blood-2019-129104

Published: 2019

Journal Articles

Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial

Gregory A. Abel, MDMPH, Hajime Uno, PhD, Anna M. Tanasijevic, MPH, Zilu Zhang, MS, Tammy T Hshieh, MD MPH, Clark T Dumontier, MD, Richard Chen, BA, Lee Mozessohn, MD, Richard M. Stone, MD, Robert J. Soiffer, MD, Jane Driver, MD MPH

Blood (2019) 134 (Supplement_1): 67.

https://doi.org/10.1182/blood-2019-126158

Published: 2019

Journal Articles

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, BMSC, Suman Biswas, MD, Sri Lekha Bodepudi, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Salman Ahmed, MD, Prachi Jani, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 71.

https://doi.org/10.1182/blood-2019-124799

Published: 2019

Journal Articles

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Marcio M Andrade-Campos, MD PhD, Laura Lopez de Frutos, PhD, Jorge J Cebolla, MSc, Blanca Medrano-Engay, PhD, Mercedes Roca-Espiau, PhD, Beatriz Gomez-Barrera, David Iniguez, Pilar Giraldo, PhD

Blood (2019) 134 (Supplement_1): 2323.

https://doi.org/10.1182/blood-2019-122347

Published: 2019

Journal Articles

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Teresa Poggio, Linda Graessel, Stefanie Kreutmair, Cornelius Miething, Dietmar Pfeifer, Geoffroy Andrieux, Melanie Boerries, Marie Follo, Suzanne Turner, Robert Zeiser, MD, Justus Duyster, MD, Anna Lena Illert

Blood (2019) 134 (Supplement_1): 2542.

https://doi.org/10.1182/blood-2019-125589

Published: 2019

Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2658.

https://doi.org/10.1182/blood-2019-129377

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Michael R. Savona, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Katherine J. Walsh, MD, Raoul Tibes, MD PhD, Karen W.L. Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, MD, Scott D. Lunin, MD, Todd L. Rosenblat, MD MS, Nikolai A. Podoltsev, MD PhD, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 2957.

https://doi.org/10.1182/blood-2019-129962

Published: 2019

Journal Articles

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Maryam Sarraf Yazdy, MD, Umair Jarral, MD, Chao Yin, MD, Frank Kuhr, PhD, Allison P. Jacob, Bruce D. Cheson, MD

Blood (2019) 134 (Supplement_1): 2813.

https://doi.org/10.1182/blood-2019-127262

Published: 2019

Journal Articles

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Binod Dhakal, MBBS, Muhammad Umair Mushtaq, MD, Ashley Cunningham, MD, Athanasios Papadas, MD, Adam Pagenkopf, BS, Joshua Wiesner, Catherine Leith, MBBChir, Peiman Hematti, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD, Fotis Asimakopoulos, PhDMBBChir,

Blood (2019) 134 (Supplement_1): 3088.

https://doi.org/10.1182/blood-2019-127565

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Genome Wide Interaction Analysis Identifies Expression Quantitative Trait Loci Associated with Reduced Survival after Reduced Intensity Conditioning HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant

Blood (2019) 134 (Supplement_1): 4595.

https://doi.org/10.1182/blood-2019-129182

Published: 2019

Journal Articles

Establishing a Novel High-Throughput Conditioning-Free HSC Transplant Model in Zebrafish

Ellen Fraint, MD, Teresa V. Bowman, PhD

Blood (2019) 134 (Supplement_1): 4423.

https://doi.org/10.1182/blood-2019-127483

Published: 2019

Journal Articles

Increased Risk of Early Hematologic Toxicity during Maintenance Therapy in Acute Lymphoblastic Leukemia Patients of South Indian Origin Carrying NUDT15*3 Allele

Sunitha Kodidela, PhD, Dorababu Patchva, PhD, Dimpal Thakkar:, PhD, Biswajit Dubashi, DM, Rajan Sundaram, M.Sc, Ravi Prasad Nidanapu, PhD, Muralidharan Nivedita, PhD, Anil Aribandi, MD MRCP, FRCPath, Suresh Chandra Pradhan, MD, Chakradhara RS Uppugunduri, PhD

Blood (2019) 134 (Supplement_1): 5059.

https://doi.org/10.1182/blood-2019-129967

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Live or die: PD-L1 delays neutrophil apoptosis

Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress

Expression of Human SBDS R126T in S bds Null Background Shows Eif6 Dysregulation: An Adult Zebrafish Model for Shwachman-Diamond Syndrome

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Sirpαfc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Computational Analysis Model Applied to Spanish Gaucher Registry Data

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Genome Wide Interaction Analysis Identifies Expression Quantitative Trait Loci Associated with Reduced Survival after Reduced Intensity Conditioning HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant

Establishing a Novel High-Throughput Conditioning-Free HSC Transplant Model in Zebrafish

Increased Risk of Early Hematologic Toxicity during Maintenance Therapy in Acute Lymphoblastic Leukemia Patients of South Indian Origin Carrying NUDT15*3 Allele

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only